Hennion & Walsh Asset Management Inc. Sells 47,371 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Hennion & Walsh Asset Management Inc. lessened its position in Exelixis, Inc. (NASDAQ:EXEL) by 75.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 15,540 shares of the biotechnology company’s stock after selling 47,371 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Exelixis were worth $517,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Farallon Capital Management LLC lifted its position in Exelixis by 1.6% during the second quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock valued at $608,993,000 after buying an additional 424,000 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Exelixis by 7.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 5,137,201 shares of the biotechnology company’s stock worth $115,434,000 after acquiring an additional 349,837 shares in the last quarter. AQR Capital Management LLC lifted its position in Exelixis by 12.7% during the 2nd quarter. AQR Capital Management LLC now owns 3,281,578 shares of the biotechnology company’s stock valued at $73,425,000 after acquiring an additional 370,199 shares during the period. FMR LLC boosted its stake in Exelixis by 6.1% during the third quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company’s stock worth $63,891,000 after acquiring an additional 140,568 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its holdings in Exelixis by 124.0% in the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after purchasing an additional 991,494 shares during the period. 85.27% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on EXEL shares. Truist Financial boosted their price target on Exelixis from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, January 15th. JMP Securities increased their target price on Exelixis from $34.00 to $41.00 and gave the stock a “market outperform” rating in a research note on Wednesday, January 15th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $34.00 price target on shares of Exelixis in a research report on Wednesday, October 30th. Stephens upped their price target on shares of Exelixis from $23.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 30th. Finally, TD Cowen upped their price target on shares of Exelixis from $27.00 to $34.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Exelixis currently has an average rating of “Moderate Buy” and a consensus target price of $35.50.

Insider Transactions at Exelixis

In other news, Director George Poste sold 30,000 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $34.00, for a total value of $1,020,000.00. Following the transaction, the director now owns 169,020 shares in the company, valued at $5,746,680. This represents a 15.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Dana Aftab sold 1,162 shares of the stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total transaction of $36,486.80. Following the completion of the transaction, the executive vice president now owns 498,945 shares in the company, valued at $15,666,873. This trade represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 314,736 shares of company stock worth $10,849,110 in the last quarter. Company insiders own 2.85% of the company’s stock.

Exelixis Stock Performance

EXEL opened at $36.20 on Tuesday. The stock has a market capitalization of $10.34 billion, a P/E ratio of 23.21, a P/E/G ratio of 0.87 and a beta of 0.53. The company’s 50-day simple moving average is $34.97 and its two-hundred day simple moving average is $29.49. Exelixis, Inc. has a 52-week low of $20.01 and a 52-week high of $37.59.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The firm had revenue of $539.50 million for the quarter, compared to analysts’ expectations of $490.31 million. During the same quarter in the prior year, the business earned $0.10 EPS. The business’s quarterly revenue was up 14.3% on a year-over-year basis. Research analysts forecast that Exelixis, Inc. will post 1.7 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.